Skip to main content
Journal cover image

Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease.

Publication ,  Journal Article
Portman, MA; Jacobs, JP; Newburger, JW; Berger, F; Grosso, MA; Duggal, A; Tao, B; Goldenberg, NA; ENNOBLE-ATE Trial Investigators,
Published in: J Am Coll Cardiol
December 13, 2022

BACKGROUND: Standard of care (SOC) anticoagulation for thromboembolism (TE) prevention in children with cardiac disease includes low molecular weight heparins or vitamin K antagonists. Limited data exists for alternate use of direct oral anticoagulants in children. OBJECTIVES: The investigators aimed to obtain safety and efficacy data for edoxaban in children. METHODS: We performed a phase 3, multinational, prospective, randomized, open-label, blinded-endpoint trial in patients <18 years of age with cardiac disease (ENNOBLE-ATE [Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease] trial). Patients were randomized 2:1 to age- and weight-based oral edoxaban once daily vs SOC for 3 months (main study period), stratified by cardiac diagnosis. Both groups could continue in an open-label edoxaban extension arm through 1 year. The primary endpoint was adjudicated clinically relevant bleeding (CRB). The main secondary endpoint was symptomatic TE or asymptomatic intracardiac thrombosis. RESULTS: The modified intention-to-treat cohort included 167 children. One patient per group experienced a nonmajor CRB in the main period. Treatment-emergent adverse events occurred in 46.8% (51 of 109) with edoxaban and 41.4% (24 of 58) with SOC. One SOC patient experienced 2 TE events (DVT with PE). Among 147 children in the extension, 1 CRB event (0.7%) and 4 TEs occurred (2.8%; 2 strokes and 2 of 33 Kawasaki disease patients with coronary artery thromboses and/or myocardial infarctions). CONCLUSIONS: Edoxaban is a potential alternative mode of thromboprophylaxis in children with cardiac disease showing low rates of CRB and TEs with advantages of once daily dosing and infrequent monitoring requirement. (ENNOBLE-ATE [Edoxaban for Prevention of Blood Vessels Being Blocked by Clots] (Thrombotic Events) in Children at Risk Because of Cardiac Disease trial; NCT03395639).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

December 13, 2022

Volume

80

Issue

24

Start / End Page

2301 / 2310

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Prospective Studies
  • Humans
  • Heart Diseases
  • Child
  • Cardiovascular System & Hematology
  • Anticoagulants
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Portman, M. A., Jacobs, J. P., Newburger, J. W., Berger, F., Grosso, M. A., Duggal, A., … ENNOBLE-ATE Trial Investigators, . (2022). Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. J Am Coll Cardiol, 80(24), 2301–2310. https://doi.org/10.1016/j.jacc.2022.09.031
Portman, Michael A., Jeffrey P. Jacobs, Jane W. Newburger, Felix Berger, Michael A. Grosso, Anil Duggal, Ben Tao, Neil A. Goldenberg, and Neil A. ENNOBLE-ATE Trial Investigators. “Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease.J Am Coll Cardiol 80, no. 24 (December 13, 2022): 2301–10. https://doi.org/10.1016/j.jacc.2022.09.031.
Portman MA, Jacobs JP, Newburger JW, Berger F, Grosso MA, Duggal A, et al. Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. J Am Coll Cardiol. 2022 Dec 13;80(24):2301–10.
Portman, Michael A., et al. “Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease.J Am Coll Cardiol, vol. 80, no. 24, Dec. 2022, pp. 2301–10. Pubmed, doi:10.1016/j.jacc.2022.09.031.
Portman MA, Jacobs JP, Newburger JW, Berger F, Grosso MA, Duggal A, Tao B, Goldenberg NA, ENNOBLE-ATE Trial Investigators. Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. J Am Coll Cardiol. 2022 Dec 13;80(24):2301–2310.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

December 13, 2022

Volume

80

Issue

24

Start / End Page

2301 / 2310

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Prospective Studies
  • Humans
  • Heart Diseases
  • Child
  • Cardiovascular System & Hematology
  • Anticoagulants
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology